RDCA-DAP®

Rare Disease Cures Accelerator
Data and Analytics Platform

HOW IT WORKS



PRE-COLLECTION PLANNING

Study sponsors must identify the patient population, biomarkers and clinical outcome assessments they wish to learn about as well as create consent forms for sharing data and consult with FDA if they plan to use this data as part of a regulatory submission



COLLECT

Engaging individuals in research in various ways, including through the collection of data in registries and clinical trials, is key



CONTRIBUTE

A study sponsor can share collected data with the secure RDCA-DAP database



EXPLORE AND STANDARDIZE

Data is prepared and curated to assure it can be optimally analyzed along with other standardized datasets in RDCA-DAP



SHARE

Researchers can request access to data and tools to support analyses that may improve disease characterization and the identification of biomarkers and clinical outcome measures

OPTIMIZE

Data and advanced analytics can shape innovative clinical trial designs that have the potential to accelerate the development of rare disease treatments

RDCA-DAP® is fully funded with a federal grant awarded to Critical Path Institute. NORD does not recommend or endorse any particular medical treatment but encourages patients to seek the advice of their clinicians.
©2022 NORD. All rights reserved. NORD® is a registered trademark of The National Organization for Rare Disorders. NORD is a 501(c)(3) charity organization. rarediseases.org NRD-2210

CRITICAL PATH INSTITUTE | NORD®